Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Keros Therapeutics, Inc. has received a consensus rating of "Hold" from brokerages, with one sell recommendation, seven hold recommendations, and seven buy recommendations among the fifteen firms covering the stock.
• The company's average twelve-month target price is $30.00, although research analyst HC Wainwright recently reduced their target price from $25.00 to $20.00 while maintaining a "buy" rating.
• Keros Therapeutics recently reported earnings of ($0.76) per share, beating analyst expectations, but its revenue of $0.02 million fell significantly short of the anticipated $3.83 million.

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned a consensus rating of "Hold" from the fifteen ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $30.00.

A number of research analysts recently weighed in on the company. HC Wainwright reduced their target price on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Weiss Ratings reissued a "sell (d)" rating on shares of Keros Therapeutics in a report on Wednesday, October 8th.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in KROS. FNY Investment Advisers LLC bought a new stake in Keros Therapeutics during the first quarter worth approximately $25,000. CWM LLC increased its holdings in shares of Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after buying an additional 2,641 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock valued at $42,000 after purchasing an additional 1,888 shares during the period. Police & Firemen s Retirement System of New Jersey raised its stake in Keros Therapeutics by 29.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock valued at $110,000 after purchasing an additional 1,892 shares during the period. Finally, Entropy Technologies LP acquired a new stake in Keros Therapeutics during the 1st quarter valued at $121,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Stock Up 1.2%

KROS opened at $15.89 on Tuesday. The company has a market cap of $645.45 million, a PE ratio of 51.26, a P/E/G ratio of 2.02 and a beta of 0.97. The business has a 50 day moving average price of $15.26 and a two-hundred day moving average price of $14.16. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The company's revenue was up 49002.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.25) EPS. As a group, sell-side analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.